Related Experiment Video
Updated: Oct 15, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Therapeutic exploration of uncommon EGFR exon 20 insertion mutations in advanced non-small cell lung cancer: breaking
Rilan Bai1, Xiao Chen1, Wei Song1
1Cancer Center, The First Hospital of Jilin University, Changchun, 130021, China.
Background:
EGFR exon 20 insertion (EGFR ex20ins) mutations account for about 10-12% of all EGFR-mutated tumors, which are usually associated with primary drug resistance to conventional EGFR-TKI therapy and worse survival outcomes, and are currently a major problem for clinicians in clinical management. In recent years, with the rapid improvement of sequencing technology and careful review of clinical data, investigators have gained a deeper understanding and clearer cognition of the clinicopathological features and molecular mechanisms of these EGFR ex20ins mutations.
Purpose:
The aim of this study was to systemically review the molecular structure and clinical characteristics of EGFR ex20ins mutations, and focus on summarizing the latest data of emerging therapies (including novel small-molecule EGFR-TKI drugs, specific monoclonal antibodies, novel drugs targeting other mechanisms, and immunotherapy) for those patients.
Conclusion:
Advances in overcoming these systemic challenges have greatly accelerated the development of new drugs targeting EGFR ex20ins, and are committed to designing more rational combination therapies to overcome or delay the emergence of drug resistance, ultimately improve the prognosis of such uncommon mutant populations.
Insights
Epidermal growth factor receptor (EGFR) exon 20 insertion mutations are resistant to standard therapies. Emerging targeted treatments show promise for improving outcomes in patients with these challenging mutations.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations occur in 10-12% of EGFR-mutated cancers.
- These mutations confer primary resistance to conventional EGFR tyrosine kinase inhibitor (TKI) therapy, leading to poorer survival.
- Recent advances in sequencing and data analysis have improved understanding of EGFR ex20ins molecular mechanisms and clinical features.
Purpose of the Study:
- To systematically review the molecular structure and clinical characteristics of EGFR ex20ins mutations.
- To summarize the latest data on emerging therapies for EGFR ex20ins, including novel small-molecule TKIs, monoclonal antibodies, other targeted drugs, and immunotherapy.
Main Methods:
- Systematic literature review.
- Analysis of clinical data and molecular characteristics.
- Evaluation of emerging therapeutic strategies.
Main Results:
- EGFR ex20ins mutations present unique challenges in cancer treatment due to drug resistance.
- Novel therapeutic agents, including small-molecule inhibitors and monoclonal antibodies, are being developed.
- Immunotherapy and combination therapies are also being explored to overcome resistance.
Conclusions:
- Significant progress is being made in developing new drugs to target EGFR ex20ins mutations.
- The focus is on designing rational combination therapies to overcome or delay drug resistance.
- These advancements aim to improve the prognosis for patients with these uncommon mutations.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
